China SXT Pharmaceuticals reports developments tied to its specialty pharmaceutical business in Traditional Chinese Medicine Pieces, or TCMPs, and TCM Homologous Supplements. Company updates describe Advanced TCMPs, including Directly-Oral TCMP and After-Soaking-Oral TCMP, as well as fine TCMPs, regular TCMPs, product-planning initiatives, and supply-chain technology projects in the traditional Chinese medicine market.
Recurring SXTC news also covers capital and listing matters, including Nasdaq compliance communications, share consolidations, registered direct offerings, and the company’s dual-class share structure. These updates connect the company’s operating focus in China with changes in its publicly traded Class A ordinary shares and related security structure.
China SXT Pharmaceuticals (NASDAQ: SXTC) will consolidate its Class A ordinary shares at a 1-for-100 ratio, effective October 26, 2026.
Post-consolidation trading is expected to begin at market opening that day under the same ticker. Class A shares outstanding will change from 68,677,498 to approximately 686,775, with fractional shares rounded up to the next whole share. The consolidation applies only to Class A shares; the 2 Class B shares will remain unchanged.
China SXT Pharmaceuticals (NASDAQ: SXTC) has agreed with purchasers to terminate their additional purchase right under its registered direct offering.
The right allowed purchasers, during the 30-day period following closing, to buy up to an additional $12 million of Class A ordinary shares and/or pre-funded warrants on the offering's terms. The termination fully removes that entitlement under Section 2.4 of the securities purchase agreement for the offering announced October 8, 2026. Securities already issued are unaffected, and all other provisions of the purchase agreement and other transaction documents remain unchanged and in effect.
China SXT Pharmaceuticals (SXTC) signed a definitive agreement with institutional investors for a registered direct offering expected to raise approximately $12 million.
The offering comprises 8,000,000 Class A ordinary shares, or pre-funded warrants in lieu thereof, at $1.50 per share, plus 8,000,000 warrants exercisable at $1.50 per share. The warrants are immediately exercisable, have a 1-year term and include a zero cash exercise option allowing holders to acquire up to 9 Class A shares per warrant. Investors also have a right to purchase up to $12 million of securities on the same terms during the 30-day period after closing. The company expects closing on or about October 9, 2026, subject to customary closing conditions. Gross proceeds exclude placement agent fees and other offering expenses.
China SXT Pharmaceuticals (NASDAQ: SXTC) will implement a 1-for-80 share consolidation of its Class A and Class B ordinary shares, effective August 10, 2026. Class A shares will begin trading on a post-consolidation basis that day, continuing under symbol SXTC with new CUSIP G2161P173.
Before the consolidation, 105,704,077 Class A shares are outstanding; afterwards, approximately 1,321,301 Class A shares will be outstanding. Every 80 shares (or part thereof) will be combined into one share, with fractional shares rounded up. All outstanding stock options, warrants and similar rights will be adjusted proportionately.
China SXT Pharmaceuticals (NASDAQ: SXTC) entered into a definitive securities purchase agreement with certain institutional investors for a registered direct offering of 4,500,000 Units at $2.00 per Unit, each Unit consisting of one Class A ordinary share and one common warrant.
Each warrant will be immediately exercisable at $3.20 per share and will expire one year after issuance. According to China SXT Pharmaceuticals, expected aggregate gross proceeds are about $9 million before fees and expenses. The transaction is expected to close on or about July 24, 2025, subject to customary conditions, with Univest Securities acting as sole placement agent.
China SXT Pharmaceuticals (Nasdaq: SXTC) announced a share re-classification effective March 24, 2026, with Class A Ordinary Shares trading under SXTC on Nasdaq. Shareholders approved in a July 28, 2025 meeting creating unlimited Class B shares with 50 votes per share and redesignating existing shares as Class A.
The re-classification became effective upon filing the amended charter with the British Virgin Islands Companies Registry; nominee-held shares will be automatically adjusted. Contact brokers or Transhare Corporation for questions.
China SXT Pharmaceuticals (Nasdaq: SXTC) will effect a 1-for-150 share consolidation of its Class A ordinary shares, effective February 3, 2026. The company expects Class A shares to trade on Nasdaq under SXTC with new CUSIP G2161P165 at market open on that date.
Prior to consolidation 143,693,892 Class A shares were outstanding; after consolidation approximately 957,960 shares are expected. Fractional shares will be rounded up. Outstanding options, warrants and purchase rights will be adjusted proportionately. Shareholders holding shares through brokers will see automatic adjustments; contact Transhare Corporation for transfer-agent support.
China SXT Pharmaceuticals (NASDAQ: SXTC) announced an AI Insight Initiative to explore applying artificial intelligence and digital tools across its Traditional Chinese Medicine raw-material supply chain. The company plans to evaluate AI-supported methods for cultivation environment monitoring, origin and authenticity assessment, quality evaluation and grading, and supply-demand forecasting and circulation efficiency. The stated goals are improved transparency, operational stability, traceability, and stronger quality oversight while preserving traditional TCM production principles.
The company said the initiative is part of long-term operational planning to support data-informed supply chain management and more reliable resource planning.
China SXT Pharmaceuticals (NASDAQ: SXTC) announced a registered direct offering of 66,666,666 Class A ordinary shares (or pre-funded warrants) at $0.15 per share, with aggregate gross proceeds expected to be approximately $10 million. The purchase price for pre-funded warrants equals the share price less a $0.001 exercise price. The offering is with a single investor and is expected to close on or about January 12, 2026, subject to customary closing conditions. Univest Securities is sole placement agent. The offering is being made under an effective Form F-3 shelf (File No. 333-291428); a final prospectus supplement will be filed with the SEC.
China SXT Pharmaceuticals (NASDAQ: SXTC) on January 8, 2026 announced a Strategic Artificial Intelligence (AI) Insights Initiative to integrate AI-driven analytics into product portfolio planning, market intelligence, and R&D decision-making for Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements (TCMHS).
The program will analyze multi-dimensional datasets—historical sales, regional health demand, product trends, and raw-material supply—to identify product opportunities, improve commercial assessments, and support lifecycle management. A planned consumer-facing rollout includes offline AI-supported TCM consultation stores ("AI Clinics") across China to provide preliminary screenings, personalized TCMP/TCMHS recommendations, and real-world feedback for R&D.